Published: 10 July 2017
In The Lancet Psychiatry, Schoeler and colleagues present a study describing the mediating effect of medication adherence on the association between continued cannabis use and relapse risk in patients with first-episode psychosis. They have previously reported a relapse rate of 36% in this patient group over a 2-year period.
Acknowledging the potential risk of psychosis relapse related to the high proportion of patients continuing cannabis use after the onset of psychosis, the current study1 investigates the same patient group consisting of 245 patients, obtaining retrospective data on active cannabis use and medication adherence shortly after illness onset, as well as risk of relapse at 2-year follow-up. The authors find that relapse of psychosis associated with continued cannabis use is partly mediated through non-adherence to prescribed antipsychotic medication.
It is well established that cannabis use increases the risk of schizophrenia, not only from the early Swedish conscript studies but also from studies on people who use sinsemilla in London, UK, showing that high potency cannabis increases the risk of schizophrenia. Twin studies from Norway have shown that cannabis increases the risk of psychosis, even when controlling for genetic factors. There has been discussion on the direction of the association, as none of these studies can rule out reverse causality, but it seems reasonable to conclude that cannabis is one of many stressors that can precipitate schizophrenia, at least in susceptible individuals.
“What do you want, what do you hate, what’s going to turn you off so I can’t ask you for money?”
This was the question the nation’s top pot lobbyist recently posed to tobacco executives in Michigan, where his lobbying group has drafted language for a recreational marijuana legalization law and is now collecting signatures to place it on the state’s 2018 ballot.
That Rob Kampia, Executive Director of the Marijuana Policy Project (MPP), went on-the-record to admit he asked this of Michigan tobacco companies is both alarming and contemptible. MPP is the lead special interest group responsible for funding and organizing every state-based marijuana commercialization campaign in the U.S. Kampia’s shameless solicitation for contributions from the tobacco industry should send chills down the spine of every American who remembers our painful national experience with Big Tobacco.
The nascent marijuana industry, which has been profiting off of high-potency commercial products, is not only following in Big Tobacco’s footsteps, but now openly admitting to taking money from them.
Make no mistake, the marijuana industry is laying the groundwork to take center stage as Big Tobacco 2.0. Tobacco companies have been eyeing marijuana as the next big addictive enterprise since the 1970’s, and now they’re getting in on this cash cow in the ultimate quid pro quo: taking money in return for shaping the language of today’s marijuana legalization initiatives
One in 5 adolescents at risk of tobacco dependency, harmful alcohol consumption and illicit drug use
Date: June 7, 2017
Source: University of Bristol
Summary: Researchers have found regular and occasional cannabis use as a teen is associated with a greater risk of other illicit drug taking in early adulthood. The study also found cannabis use was associated with harmful drinking and smoking.
The University of Chicago, Department of Psychiatry Behavioral Neuroscience, 5841 S. Maryland Ave., MC3077, Chicago IL 60637, United States
Present address: The University of Illinois at Chicago, Department of Psychiatry, 1601 W. Taylor St., MC912, Chicago, Illinois 60612
•We assessed effects of delta-9- tetrahydrocannabinol (THC) on responses to the Trier Social Stress Test (TSST) in healthy volunteers.
•THC produced nonlinear dose effects upon emotional responses to the TSST.
•7.5 mg THC dampened negative emotional responses without influencing performance.
•12.5 mg THC slightly but significantly increased negative affect overall.
•12.5 mg THC impaired TSST performance and attenuated blood pressure responses.
Cannabis smokers often report that they use the drug to relax or to relieve emotional stress. However, few clinical studies have shown evidence of the stress-relieving effects of cannabis or cannabinoid agonists. In this study, we sought to assess the influence of delta-9-tetrahydrocannabinol (THC), a main active ingredient of cannabis, upon emotional responses to an acute psychosocial stressor among healthy young adults.
In comparison to placebo, 7.5 mg THC significantly reduced self-reported subjective distress after the TSST and attenuated post-task appraisals of the TSST as threatening and challenging. By contrast, 12.5 mg THC increased negative mood overall i.e., both before and throughout the tasks, and pre-task ratings of the TSST as threatening and challenging. It also impaired TSST performance and attenuated blood pressure reactivity to the stressor.
Our findings suggest that a low dose of THC produces subjective stress-relieving effects in line with those commonly reported among cannabis users, but that higher doses may non-specifically increase negative mood.
2 June 2017
The teenager's father is backing Lord Monson's call for skunk to be reclassified
Credit:Matthew Fearn/PA wire
Ateenage rugby player cut off his own penis and stabbed his mother while high on skunk, his father has revealed, as he called for the drug to be reclassified.
The father, named only as Nick because he wants to remain anonymous as his son is rebuilding his life, is backing Lord Nicholas Monson's campaign to have skunk reclassified from a class B to a class A drug and for the traditional weaker form of cannabis to be decriminalised.
Lord Monson launched his call following the suicide of his 21-year-old son Rupert, who was addicted to skunk.
Taking Action - Stopping Ice
United Nations Office of Drugs & Crime: Drug Prevention & Treatment
Medicinal Cannabis –
Access to medicinal Cannabis Products (TGA)
Access to medicinal cannabis products: steps to using access ...